# Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

> **NCT02821052** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1355 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** insulin degludec/insulin aspart

## Key facts

- **NCT ID:** NCT02821052
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2018-11-24
- **Final completion:** 2018-11-24
- **Target enrollment:** 1355 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821052, "Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02821052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*